Clinical Trials - April 20, 2022
New results from Lundbeck’s vortioxetine trial
Lundbeck recently completed a global Phase IV, randomized, comparative study exploring the role of vortioxetine as a treatment option between SSRIs and serotonin–noradrenaline reuptake inhibitors (SNRIs). The efficacy of vortioxetine was directly compared to one of the latest introduced SNRIs, desvenlafaxine, as monotherapy. The study, called VIVRE, recruited a total of 605 patients across 12 […]
In a new job - April 12, 2022
Lundbeck appoints new CFO and Head of Corporate Functions
Lundbeck has announced that Joerg Hornstein is appointed Chief Financial Officer (CFO) and member of Lundbeck’s Executive Management. He will assume the role no later than September 1, 2022. “Following a thorough internal and external search, we are delighted to welcome Joerg to Lundbeck. He brings extensive experience in delivering results and creating value across […]
Pharma Business - January 25, 2022
Lundbeck’s Vyepti approved in the EU
The European Commission has granted marketing authorization for Vyepti in the European Union for the prophylactic treatment of migraine in adults who have at least four migraine days per month. The approval follows the positive opinion on November 11th, 2021 from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). Vyepti […]
In a new job - December 7, 2021
Lundbeck’s CFO leaves the company
Lundbeck has announced that Anders Götzsche, Chief Financial Officer (CFO), will depart Lundbeck to become CFO of another company in Denmark. He will leave Lundbeck no later than May 2022. “Anders has been CFO of Lundbeck for over 14 years, including a short stint as interim Chief Executive Officer in 2017-2018. He has been instrumental […]
In a new job - November 30, 2021
Lundbeck announces executive management changes
Lundbeck has announced that Jacob Tolstrup, Executive Vice President for Commercial Operations, is promoted to Chief Commercial Officer, effective 1 January 2022. Jacob will be responsible for sales and marketing across all Lundbeck affiliates worldwide. Also, Peter Anastasiou, Executive Vice President for North America, has decided to leave Lundbeck at the end of the year […]
Clinical Trials - November 16, 2021
Lundbeck launches phase II study
Lundbeck has expanded its clinical-stage pipeline and initiates the AMULET study, which is designed to confirm the potential of Lu AF82422 as a treatment to slow the rate of disease progression of multiple system atrophy (MSA). Earlier this year, Lu AF82422 was granted orphan drug designation by the European Medicines Agency (EMA), and the AMULET […]
